GI
ROIV icon

GAMMA Investing’s Roivant Sciences ROIV Stock Holding History

GAMMA Investing’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$651K Buy
17,791
+3,154
+22% +$114K 0.02% 582
2026
Q2 		$518K Buy
14,637
+2,172
+17% +$64.2K 0.02% 637
2026
Q1 		$345K Buy
12,465
+1,426
+13% +$36.6K 0.02% 762
2025
Q4 		$240K Buy
11,039
+1,737
+19% +$34.3K 0.01% 908
2025
Q3 		$141K Buy
9,302
+1,324
+17% +$16.4K 0.01% 1218
2025
Q2 		$89.9K Buy
7,978
+1,485
+23% +$16.1K 0.01% 1535
2025
Q1 		$65.5K Buy
6,493
+2,945
+83% +$31.8K ﹤0.01% 1594
2024
Q4 		$42K Buy
3,548
+1,288
+57% +$15.2K ﹤0.01% 1793
2024
Q3 		$26.1K Buy
2,260
+167
+8% +$1.9K ﹤0.01% 1946
2024
Q2 		$22.1K Buy
2,093
+836
+67% +$9.16K ﹤0.01% 1789
2024
Q1 		$13.2K Buy
1,257
+116
+10% +$1.25K ﹤0.01% 1895
2023
Q4 		$11.4K Buy
+1,141
New +$11.1K ﹤0.01% 1836

Other funds holding ROIV

TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
FFAS
FIG Financial Advisory Services Oklahoma City, Oklahoma $165M AUM 16.79% 1-Year Est. Return
LWA
Ledgewood Wealth Advisors Exeter, New Hampshire $181M AUM 9.93% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.62B AUM 25.73% 1-Year Est. Return
WPC
Wedmont Private Capital West Chester, Pennsylvania $4.18B AUM 18.65% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
DLA
Douglas Lane & Associates New York $7.46B AUM 24.36% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
AIM
Acropolis Investment Management St. Louis, Missouri $2.49B AUM 10.8% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

GAMMA Investing's ROIV Position: Q3 2026 in Review

GAMMA Investing increased its Roivant Sciences (ROIV) stake by 22% in Q3 2026, buying an estimated $114K and bringing the position to 17,791 shares worth $651K. The position accounts for 0.02% of the portfolio, ranked #582.

GAMMA Investing first reported a position in ROIV in Q4 2023 and has held it in 12 quarters since. 20 funds tracked by Wall St. Rank hold ROIV as of Q3 2026.

  • GAMMA Investing held 17,791 shares of Roivant Sciences worth $651K as of Q3 2026.
  • GAMMA Investing bought 3,154 Roivant Sciences shares in Q3 2026, an estimated $114K.
  • Roivant Sciences made up 0.02% of GAMMA Investing's portfolio in Q3 2026, its #582 holding.
  • GAMMA Investing first reported a position in Roivant Sciences in Q4 2023 and has held it in 12 quarters since.
  • 20 funds tracked by Wall St. Rank held Roivant Sciences as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.